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ABSTRACT 
In vitro release profiles were obtained for eight topical creams containing 0.05% 
(W /W) fluocinon.ide, a. new topical corticoid. Four of these creams plus five ointments 
containing 0.05% (W /W) fluocinonide were tested for vehicle efficacy in t·it•o utilizing 
a modified toughton-1'1'1 rKenzie as-ay for vasoconstriction. A rank order correlation 
was obtained between release, percent drug solubilized, and vasoconstrictor response 
for the creams. A similar correlation existed between percent drug solubilized and vaso-
constrictor response for the ointments. The results demonstrated 1) the signifi cance 
of vehicle composition, 2) the importance of drug solubility in the vehi cle. and 3) the 
usefulness of in vitro release stuclies in preclicting vehicle efficacy. 
In the design of vehicles for topical drugs, the 
formulator must consider se\·eral aspects of ve-
hicle composition in order to insure that the 
final p roduct will have the desired properties. 
The vehicle must be physically st.able and cos-
metically acceptable. It must also pro\':ide an 
environment in which the drug is stable and 
from which the drug is reaclily released when 
placed in contact with skin. 
Drug availability for topical dosage fo rms is an 
important consideration because it can deter-
mine the ease or difficulty "ith which the drug 
will penetrate the skin barrier. Improper formu-
lation can render a potent topical drug essen-
tially ineffective. Pre\ious reports (I , 2) have a) 
demonstrated t he signi.ficance of vehicle compo-
sition, b) characterized the relationship between 
release, penetration and in vivo response and c) 
provided a means of predicting optimal vehicle 
composition fo r some gels. This study was de-
signed a) to characterize the release of a new 
topical steroid, fluocinonide1 (3, 4) from several 
creams and ointments and b) to determine the 
effect of vehicle composition on release and in 
vivo response. Although for many clinical situa-
tions the penetration of the drug ac ross the skin 
barrier is probably rate determining, the release 
rate of the drug from the vehicle is dependent 
on the same cliffusiona.! parameters. These cliffu-
sional parameters include the diffusivity of the 
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drug in the barrier or the \·ehicle (D), the parti-
tion coefficient of the drug between the vehi cle 
and skin or the vehicle :1nd some receptor fluid 
(PC) , and the conr.entration of drug in solution 
in the vehicle (C.). When the minimum amount 
of soh·ent is used to completely clissolve the 
drurr in a \·ehicle and yet maintain a favorable 
partition coefficient, the diffusion of the drug out 
of a vehicle or ac ross a barrier is maximized for 
many topical preparations. This may not be true 
if PC is a dominant factor relative to C. in skin 
penetration in which rase a Yehicle in which the 
drug is suspended may be best to facilitate pene-
t ration (1) but not relea e. Except for tl:ris lat-
ter case, a study of drug release from a vehicle 
can be used to precli rt vehicle effects on skin 
penetration. 1aximizing the release rate also 
pro\ides conditions fo r optimal penetration even 
though the rate lin:riting step is penetration of 
the skin barrier. 
Two physical parameters which are important 
in determining release characteristics are the 
concentration of drug in solution in the vehicle 
(C.) and the partition coefficient of the drug 
between the skin and the vehicle (PC). The 
relative importance of these parameters is de-
pendent on the physical-chemical character 0 1 
both the drug and vehicle. C. is important be-
cause only the fract ion of drug which is solubi-
lized can reaclily diffuse out of the vehicle. P C' 
plays a role because the skin normally does no1 
provide sink conditions for release.' 
Theoretically, it can be shown that for releas• 
' When sink conditions do exist, the PC car 
play no role in dru~ release since the rate de· 
termining proce._"S is diffusion within the vehicle. 
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from topical ,·ehicles, a gi1•en drug will be re-
leased fastest from a system in which the drug is 
completely solubilized (assuming that other pa-
rameters such as l·iscos.ity, remain constant). If 
the drug is in solution. the ,·ehicle is homogene-
ous and sink conditions preYail, then the amount 
of drug released per unit area, Q, , is given by 
Equation 1 (5). 
[ 
8 X 1 Q, = hCo 1 - - L ---
1f'' m-o (2m + 1)1 
(
-D(2m + l )'1r't)] 
CJI.'p 4h' 
Eq. 1 
D is the diffusion coefficient for the drug in the 
Yehicle, h is the thickness of the 1·ehicle, c. is 
he initial drug concentration. m is an integer, 
and t is time. For small t , when only the fi rst 
term of the sum in Equation 1 is significant, the 
relationship simplifies to 
Eq. 2 
However, if a substantial fraction of the drug is 
in the form of a suspension. it has been shown 
(6} that 
Q, -:c,.- c., [1+ ,,~,;:c.,]" ···' 
If A » C, , then Equat ion 3 simplifie- to 
Q,""' (2.1DC,I)•~ Eq.4 
From Equations 2 and 4, one can 
following relationship 
obtain the 
Q, = [ 7f'4.~J'' Q, Eq. 5 
When c. is set equal to A. in the case of Q, . 
ince the proportionality factor ( -lA/ 1rC,) '" is 
greater than one, Q, > Q, (A>> C,). Thus. at a 
given concentration, release is always faster 
from the vehicle in which the drug is completely 
solubilized. The general goal in topical vehicle 
formulation is to maximize the release rate with-
out unfavorably altering other relevant 1·ehicle 
properties. 
Since the solubility of a drug in its vehicle is 
an important factor determining a1·ailability, 
measuring or estimating this parameter would 
be helpful in the design of topical vehicles. Al-
though it is difficult to experimentally determine 
drug solubility in a semisolid mixture, it is possi-
ble to make reasonabl estimations which have 
fill ~ TEFLON RING 
~------ F 1L TE R 
~-««t«<= ~~~~~N CELL 
Fro. 1. Cell used for release from creams 
practical nlue. For the creams and ointments 
studied in this report, it was as.:.-umed that the 
solubility of the drug in the vehic.le could be 
attributed mainly to its solubility in one or two 
of the vehicle components. The contribution to 
total solubility made by solids and poor solubil-
izers such as stearyl alcohol, polyethylene glycol 
and petrolatum wa considered negligible. For 
each vehicle, the problem then was one of esti-
mating the drug ~olubility in a relatively simple 
system. The solubility of the drug in each for-
mulation was estimated by one or both of the 
following methods: 
1] interpolation from a plot of known e-xperi-
mental solubilities in pure liquids versus cal-
culated frac.tional molar attraction constants 
as discussed in a previous report (7), 
2] interpolation from a plot of log solubility 
Yer-us the Yolume fraction of one oomponent 
in the liquid solubilizer phase.' These estima-
tions '1\ere made "~th the following assump-
tions: a) the solubilizing components of each 
formulation mix well and can be considered a 
single phase (Phase 1) , b) the solubilizing 
phase does not mix with the remainder of the 
formulation (Phase 2), c) the drug solubility 
in Phase 1 is not affected by the presence of 
Phase 2, and d) the drug solubility in Phase 
2 is negbgible. 
MATERIALS A-"D METHODS 
In Yi tro reloose. Three grams of the prepared 
creams were fil led into Teflon cells haYing a di-
ameter of 3.0 em and n depLh o( 0.4 em (see Fig. !) . 
A disc of fil ter paper' dampened with isopropyl 
myristatc' was placed on the urface of the cream 
taking care to eliminate air bubbl s. Teflon rings 
were placed oYer the filter paper to hold the cream 
in place. 
The Teflon cells containing tbe cream were 
placed in beak rs containing 200 mJ. of isopropyl 
myristate. Stirring blades ( i .5 X 2.5 em) were low-
ered halfway into the receptor phase. The receptor 
phase was stirred at either 50 RPM (Cream Set IT) 
• The use of this method has no rationale ex-
cept that for the binary mixtures in which solubili-
ties were determined. the ru.']>Cfimental and esti-
mated values agreed fairly well. 
• iVhatman Filter No. 54. 
• General Aniline & Film Corp., New York. 
New York. 
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TABLE I 
Ql!alitaiive composit·ion of F.1PG® crctt>rt" 
Cream til 
Set 1 
3 
-! 
Discontinuous 
matrix phase 
f Carbowa.x 4000 
}
. Fatty aJcobol 
Carbowax 4000 
}
Fatty aJcohol 
Carbowax 6000 
, Fatty ulcobol 
Cont.inuous 
solubilizer phase 
Propy lene glycol l 
f 
PropyleHe glycol l 
Glyceriu [ 
Propylellt' glycol l 
Water } 
%Drug 
soh.Jbilized 
JOO 
84 
48 
U8 Set) I 
lPolyviu~-1 pyrolidone 1 
5 Vanishing Type Cream <0.2 
100 
100 
lOU 
(j 
Set Ill 
8 
{ Carbowax 6000 I Hexanetriol ' Fatty aJcohol Propylene glycuiJ 
or 25 RPM (Cream Seis I and III) by a multiple 
stirring apparatus.' The releru;e apparatus was kept 
in a water bath au 25" C. 
Aliquots of the isopropyl myristate were re-
moved periodicall~- from each beaker and mixed 
v-.ilh 10 rnl of scintilla tion fluid. The fluid consisted 
of 4 gm of 2,5-diphenyloxazole,' OJ grn of 1,4-
Bis[2-( 4-methyl-5-phenyloxazolyl)] benzene' in one 
liter of scintillation grade Toluene' The samples 
were then counted on a liquid scintillation counter' 
V asocomtrictor studies. The vasoconstrictor 
studies were performed using the method devel-
oped by McKe02ie and Stoughton (8) and modi-
fied by Burdick et al. (9). The different formula-
tions were applied to healthy subject· who had 
not participated in an.\• study using steroids for at 
least four weeks prior to testing. Each subject was 
treated on both forearms with each formulation at 
two randomized locations for a total of 16locations 
using 3 millig;rams of preparation per i x 7 rom-
square sites punched in double-adhesivecoated 
tape.'• After the application of the formulations, 
one forearm was covered with a plastic film.u Six 
hours after application the forearms were washed 
and allowed to remain open. The sites responding 
were recorded at 8, 24 . and 32 hou rs after applica-
tion . 
RESULTS AND DISCUSSION 
Creams 
Two different types of cream formulations 
containing 0.05o/o (W /W) fluocinonide were in-
vestigated. A total of eight formulations were 
• Phipps and Bird, Inc., Richmond, Va. 
7 Arapahoe ChemicaJs, Div. Syntex Corp., 
Boulder. Colorado. 
• Matheson Coleman and Bell, Norwood, Ohio. 
• Nuclear Chicago Corp., Model #720, Des 
Plaines, ILL 
10 Blenderm®. 
llSaran Wrap®. 
studied. One oi the eight (Cream l) was a con-
ventional oil-in-water emulsion of the type com-
monly referred to as a mnishing cream. The 
components of this ,-ehicle (in addition to fluoci-
nonide) were stearic acid , propylene glycol, sor-
bitan monostearate and monooleate, polyoxy-
eLhylene sorbitan monostearate, citric acid, 
methyl paraben, prop~'] p:uaben and water 
(7 5%). Since the major component of this vehi-
cle is water, it possesses very little solubilizing 
capability for highly insoluble compounds such 
as fluocinonide. Most of uhe steroid is present as 
undissoh·ed, small partieles of solid drug. 
The remaining seven cream formulations were 
variations of a novel, ne'" topical vehicle" which 
appears to be particularly well suited as a deliv-
ery system for poorly soluble compounds such as 
topical corticosteroids. The vehicles may be de-
scl'ibed as two phase systems in which a continu-
ous, solubilizing phase is distributed in a solid 
matrix of fatty alcohol and high molecular 
weight polyols. These vehicles have been termed 
cream/gels since they combine the physical 
properties of gels with the cream-like appear-
ance and consistency of emulsion systems. 
The qualitative compositions of the creams 
are given in T able I where they are grouped into 
three Sets. The release for the creams in Sets I 
and ill was obtained using a stirring rate of 25 
RPM and should not be compared to the release 
for the creams in Set II which was obtained 
using a stirring rate of 50 RPM. The cream 
components which were considered to be signifi-
cant in affecting the capacities of the prepara-
,. Called FAPG® Cream Base. 
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FIG. 2. Fluocinonide release from various creams into isopropyl m~·ri:.tate ar 2ii' C. 
• Cream il! l , lL Cream il! 2, • Cream #3 (set I) 
tions fo r the drug were propylene glycol, water, 
hexanetriol, and glycerin and are listed in Table 
l as the solubilizer phase. The percent drug solu-
bilized for each formulation was estimated by 
one of the methods prmiously described in this 
report . Plots of cumulative amounts released as 
a function of time for the three creams in Set I 
are given in Figure 2 along with the estimated 
percent drug solubilized. The solubility of the 
drug in the vehicle was nried by replacing some 
of the propylene glycol with glycerin . It is rec-
ognized that the viscositie- of the creams can 
have an eJiect on release rate. Although these 
viscosities were not determined, a physical ex-
amination suggested that they were not signifi-
cantly different and would not be a dominant 
factor determining the relative release rates. In 
terms of rank order , the cumulative amount re-
leased is seen to correlate with the percent drug 
solubilized. Tlus result corresponds to what one 
would predict based on Equations 2 and 4 de-
scribing the diffusion of molecules in semisolids. 
That is , only the solubilized drug molecules can 
diffuse within the vehicle and contribute signifi-
cantly to the release rate. In terms of efficacy 
then, there is a distinct adnntage in completely 
solubili zing the drug. The release profiles for the 
four creams in Set II are gi,·en in Figure 3. As 
with ~et I , the amount.s rele!J.Sed at a given time 
rank in the same order as the percent drug solu -
bili zed. The shape of the profiles in Figure 3 
exlllbit a pattern which appears to be dependent 
on the solubility of t he drug in the ,·ehicle. The 
profile for Cre..1m ~6 in ,,·hich all of the drug is 
solubilized follows a square root of time depend-
ence as Equation 2 predicts. The profiles for 
Creams %3 , 4. and 5. howe,'er, do not show t lus 
dependence and are apparently not described by 
Equation 4. The release for t,hese t hree creams 
approaches linearity after a short period of time. 
This result suggests that the release may be de-
t ermined by the rate of dissolution of the insolu-
ble drug fraction within the ,·ehicle. For these 
creams the time required to establish this appar-
ent linear dependence of release on time in-
creases a.s the percent drug solubilized increases. 
This re..."lllt is congruent with an initial diffusion 
of the solubilized fraction out of the vehicle fol-
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Fla. 3. Fluocinonide release from various creams into isopropyl myristale at 25' C. 
• Cream !!13, Jt. Cream $4, • Cream !!15, D Cream 1116 (set II ) 
12 
HOURS 
FIG. 4. Fluocinonide release from various creams into isopropyl myristate at zs•c. 
• Cream ;j/6, £::,. Cream ;j/7, 0 Cream ;j/8 (set III) 
lowed by a dissolution of the undissolved frac-
tion at large t. Using the release data for Cream 
'#6 and Equation 2, D was calculated to be 5.7 
X w-• cm'sec·' at small t and is in the range one 
might expect. 
In et III the solubility of the drug in the 
vehicle was varied by replacing some of the pro-
pylene glycol "ith hexanetriol. The correspond-
ing release profiles are given in Figure 4. There 
appears to be no dependence of release on com-
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TABLE II 
Vasocon.<lridor results for various 0 .05% fluocinom:d e crea.ms (cwerage 5 expen·m.ents) 
% Open application ( ______ o_ccl_u_d_ed_•_P_P_Iic_a_ti-on _____ _ 
-c-;-.--~--~--so-·:-·:-~-:-·d-1--j-i-' -~!1 -o/,_·2-;-;-~-~rll T~· /--8-;;-~-- ~~-_:_·j-~_:·_·-~-p-on-~;-;-,·-'- 1 ---;-;-i_'_ 
ii' 6 100 I .1_5 64 63 172 I 79 I 58 to 1 198 
position or percent drug solubilized. However, 
fo r all three creaiDB, the drug is completely solu-
bilized so that the concentration gradient for 
release is the same in each. This result indicates 
that additional solubilizer does not affect release 
m t his case at least for the r:mge of solubilizer 
studied. 
Creams l(i3-6 were tested in an in vivo assay , 
a modified Stoughton-McKenzie assay (9) and 
the results are ginn in Table II. The percent 
5-ites responding (vasonconstri ction) at 8, 2-4, 
and 32 hours \Yere recorded for both open and 
occluded application. Since the choice of time at 
which to record the response is arbitrary, the 
total points given in Table II i- probably the 
best measure of response or efficacy. In terms of 
rank order the in vivo response for both open 
and occluded application correlated with percent 
drug solubilized in t.he ''elude and with in vitro 
release rates. The results fo r open application 
more clearly differentiate the effectiveness of the 
creams. The comparative results for solubility, 
release, and in vivo responEe are summarized in 
Table III . The correlation between solubility, 
release, and in vivo response demonstrates 1) 
the significance of vehicle composition, 2) the 
importance of drug solubility in the vehicle, and 
3) the usefulness of in vitro release studies in 
predicting \'chicle efficacy. 
Ointments 
Five ointment fo rmulations containing 0.05% 
(W (W) fiuocinonide were investigated. Their 
qualitative compositions are given in Table IV_ 
Except for Ointment $1 which had no solubil-
izer, the ointments consisted of a 5% solubilizer 
phase composed of carbitol or a propylene gly-
col-propylene carbonate mixture dispersed as 
t.he internal or discontinuous phase in petrola-
TABLE IU 
Comparative tJ·ol'Ubilily. in 'irrh rrlen..'ie a.nd va;-.;o-
con.r.:lriclion of l'ariou x 0.05t ·~ jluocinonide c1·eams 
% Drug I I Total %site.s Cream Total release at solubilized i hour!; 1 •c:.m:! 
Open 
rt5 <0.2 3.0 95 
rt 3 48 39. 7 120 
ft~ f,8 5--lA 151 
ft6 ] ()() 57 .2 172 
tum '~it.h the aid of various emulsifiers. This 
then is one major difference as compared with 
the cream/ gel fo rmulations described previously 
where the st-eroid is solubilized in the external or 
continuous phase of the formulation. In making 
the estimates of percent drug solubilized, the 
ointment components considered to be signifi-
cant were propylene glycol, propylene carbon-
ate, carbitol, sorbitan sesquioleate. ancl polyoxy-
etbylene sorbitan monoolea e. Release ex-peri-
ments wer attempted but no significant release 
was ob ::tined. This fi nding is not surprising since 
the steroid solubility in the e::-.iernnl petrolatum 
phase is Yery low. The solubility of fiuocinonide 
in heptane, for example, is ,....,w-• mg.(ml. and 
the solubility in petrolatum is mas likely similar_ 
One can estimate the effecti\'e diffusion coeffi-
cient, D, , for the drug in these ointments utiliz-
ing the expression 
D. = D, 
v. + 1\.'1', 
Eq. 6 
-[1 + 3V, ( KD,- D, )] 
KD, + 2D1 
deduced by Higuchi (10) for two phase emulsion 
type ointmen.ts. D, and D , are the diffusion coef-
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TABLE IV 
Qualitative composition o( ointm-ents 
Ointment Discontinuous c~ntinuous Emulsifiers 
" 
solubilizer phase matrix phase 
1 none Petrolatum 1\one 
2 {Propylene glycol Petrolatum Sorbitan sesquioleate Propylene carbonate Cholesterol Polysorbate 80 
Fatty alcohol 
{ Carbitol Petrolatum i"orhi tan sesquioleate 
3 Cholest.erol Polysorbate 80 
Fatty alcohol 
-! Carbitol Petrolatum l:iorbit.atl sesquioleate 
5 {Propylene glycol. Petrolatum Amerchol CAB 
I Propylene carbonate 
TABLE V 
Va.soconslriclor results for vario11s 0.05% fluoC'inonide ointments (a11emgr of II experiments) 
Open application 
Ointment 
% 
sol~~ed %Sites responding at 
8 hr I 24 hr I 32 hr I I 
!Ill 0 No data 
#2 36 62 31 22 
#3 46 68 28 31 
#4 56 89 38 39 
#5 100 87 46 40 
ficients in the external and internal phases re-
spectiYely, V, and V, are the volume fractions of 
the external and internal phases respectively, 
and K is the equilibrium partition coefficient 
defined as the ratio of the drug concentration in 
Phase 2 to the drug concentration in Phase 1. 
For the ointments under consideration, V, » V, 
and since the internal phase is a liquid "bile the 
external phase is a semisolid, D, » D,. There-
fore, Equation 6 simplifies to 
Occluded application 
% Sites responding at 
Total 8 br I 1-1 br 
I 
32 hr Total 
51 43 30 123 
115 87 45 45 177 
127 85 3G 30 157 
164 88 41 
I 
37 172 
li5 91 56 47 194 
The ointments were tested in the modified 
Stoughton-McKenzie assay and the data are 
given in Table V along with the estimated solu-
bilities. As with the in vivo results for the 
creams, there is a good rank correlation between 
percent drug solubilized and percent sites re-
sponded. The results for open application agrun 
more clearly differentiate the effectiveness of the 
preparations. Although release was poor, the in 
vivo results were good. A possible e};planation is 
D, = :~. (1 + 3V,) 
that the whole vehicle is absorbed or that the 
Eq. 7 ointment separates when it is applied." 
Y, ""' 0.05. D can be estimated to be in the 
range of 1o-•-w-• cm'sec-' and K can be esti-
mated as the ratio of solubilities. For Ointment 
f/5 , K ""' IO' so that D, is estimated to be 
10-'"'-10-" cm'sec-'. The insignificant release 
from these ointments then is associated with a 
small value for D • . 
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